LVTX Stock Overview
A clinical-stage immuno-oncology company, focuses on developing cancer treatments. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
LAVA Therapeutics N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.98 |
| 52 Week High | US$6.47 |
| 52 Week Low | US$0.88 |
| Beta | 0.55 |
| 1 Month Change | -19.36% |
| 3 Month Change | -40.86% |
| 1 Year Change | -41.57% |
| 3 Year Change | -80.44% |
| 5 Year Change | n/a |
| Change since IPO | -93.18% |
Recent News & Updates
Recent updates
Revenues Working Against LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Share Price Following 25% Dive
Jun 02
LAVA Therapeutics (NASDAQ:LVTX) Has Debt But No Earnings; Should You Worry?
Mar 01LAVA Therapeutics: Assessing A Promising Innovator
Oct 18LAVA Therapeutics GAAP EPS of -$0.31 beats by $0.30, revenue of $0.47M beats by $0.11M
Sep 13Shareholder Returns
| LVTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.9% | -0.1% | -0.5% |
| 1Y | -41.6% | -6.4% | 23.2% |
Return vs Industry: LVTX underperformed the US Biotechs industry which returned -6.4% over the past year.
Return vs Market: LVTX underperformed the US Market which returned 23.2% over the past year.
Price Volatility
| LVTX volatility | |
|---|---|
| LVTX Average Weekly Movement | 13.7% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: LVTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LVTX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 37 | Steve Hurly | www.lavatherapeutics.com |
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer.
LAVA Therapeutics N.V. Fundamentals Summary
| LVTX fundamental statistics | |
|---|---|
| Market cap | US$26.82m |
| Earnings (TTM) | -US$27.64m |
| Revenue (TTM) | US$7.35m |
3.5x
P/S Ratio-0.9x
P/E RatioIs LVTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LVTX income statement (TTM) | |
|---|---|
| Revenue | US$7.35m |
| Cost of Revenue | US$154.00k |
| Gross Profit | US$7.19m |
| Other Expenses | US$34.83m |
| Earnings | -US$27.64m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.05 |
| Gross Margin | 97.90% |
| Net Profit Margin | -376.34% |
| Debt/Equity Ratio | 17.4% |
How did LVTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 02:54 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
LAVA Therapeutics N.V. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yu He | H.C. Wainwright & Co. |
| Christopher Howerton | Jefferies LLC |
| Roger Song | Jefferies LLC |